Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01996046 · ClinicalTrials.gov registry record
FDG PET/CT in Breast Cancer Bone Mets
A clinical trial of Estrogen Receptor-positive Breast Cancer and Bone Metastases, sponsored by University of Pennsylvania.
- Active
- Registry status
- 75
- Enrollment target
- 1
- Study location
NCT01996046 is a study of Estrogen Receptor-positive Breast Cancer and Bone Metastases that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 75 participants, below the 255-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01996046, a study of Estrogen Receptor-positive Breast Cancer and Bone Metastases, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change in uptake after the repeat scans will be compared to clinical long term outcomes such as time to progression and overall survival. In addition the uptake will be compared to the incidence of skeletal related events that are common occurrences in patients with cancer that has spread to the bones.
Conditions Studied
Interventions
- OTHER FDG PET/CT scan
Study Locations (1)
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2013-09 |
| Est. Completion | 2026-07-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01996046
The ClinicalTrials.gov registry entry for NCT01996046 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 255-participant average among 16 other Estrogen Receptor-positive Breast Cancer trials with a reported enrollment target (71% lower). The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Estrogen Receptor-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which FDG PET/CT scan is the first listed.
NCT01996046 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01996046 about?
NCT01996046 is a clinical study titled "FDG PET/CT in Breast Cancer Bone Mets". This study will evaluate baseline uptake on a FDG PET/CT scan in patients with breast cancer that has spread to the bones. A repeat FDG PET/CT scan will be done 4 weeks after the start of new breast cancer hormone treatment and again at 12 weeks after treatment start. The baseline uptake and change ...
What is the current status of trial NCT01996046?
This trial is currently active not recruiting. The enrollment target is 75 participants. The study started on 2013-09. Estimated completion is 2026-07-31.
What conditions does trial NCT01996046 study?
This clinical trial studies the following conditions: Estrogen Receptor-positive Breast Cancer, Bone Metastases.
What interventions are being tested in trial NCT01996046?
The interventions under investigation include: FDG PET/CT scan (OTHER).
Who is sponsoring clinical trial NCT01996046?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01996046 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Estrogen Receptor-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Breast Re-irradiation After Second Ipsilateral Lumpectomy
RECRUITING · NA
-
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
RECRUITING · Phase 2
Explore more on PlainTrial
Estrogen Receptor-positive Breast Cancer
All registered trials for this condition
Bone Metastases
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.